生命科学资讯

Sanofi keeps mum on future of disappointing Denali pact after scrapping final RIPK1 inhibitor

AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities

Repertoire adds Lilly to range of Big Pharma partners in autoimmune deal worth up to $2.69B

Sanofi says its €15B dealmaking budget, R&D spend should help ease looming Dupixent patent cliff

Thermo Fisher: Q4 Earnings Snapshot - kare11.com

Flagship's Repertoire gets another autoimmune partner in Lilly

Thermo Fisher Scientific earnings beat by $0.12, revenue topped estimates - Investing.com

Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results - Business Wire

Lonza Sets Date for 2026 Ordinary General Meeting - TipRanks

Tenpoint gets FDA nod for presbyopia eye drop and $235M

Lonza’s Capsules Sale Talks Are Nearing The Finish Line - Finimize

Narrow-Moat Lonza's Long-Term Outlook Driven by Strong Outsourced Drug Manufacturing Demand - Morningstar

The new rules of biopharma M&A: 4 trends driving dealmaking this year

Correction: Down-regulated GAS6 impairs synovial macrophage efferocytosis and promotes obesity-associated osteoarthritis

Feeding rates in sessile versus motile ciliates are hydrodynamically equivalent

Branched actin polymerization drives invasive protrusion formation to promote myoblast fusion during mouse skeletal muscle regeneration

Mitochondrial protein carboxyl-terminal alanine-threonine tailing promotes human glioblastoma growth by regulating mitochondrial function

Gut microbe-derived trimethylamine shapes circadian rhythms through the host receptor TAAR5

ChenMed CEO warns against GLP-1s for seniors

Round three of IRA negotiations is expected to be ‘manageable’ for pharma